NCT06622005 2026-04-21
SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Roswell Park Cancer Institute
Phase 1 Recruiting
Roswell Park Cancer Institute
City of Hope Medical Center
Hackensack Meridian Health
K36 Therapeutics, Inc.
Regeneron Pharmaceuticals